Abstract:Thrombotic thrombocytopenic purpura (TTP) is a particular form of thrombotic microangiopathy typically characterized by microangiopathic hemolytic anemia, profound peripheral thrombocytopenia, and a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (acronym for A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs [13th member of the family]). ADAMTS13 deficiency is usually severe (<10% of normal activity) and results from autoantibodies directed to ADAMTS13 (acquired TTP) or from biallelic mutations of the encoding gene. In some cases, acquired TTP occurs in association with specific conditions that must be identified for appropriate management: a HIV infection, a connective tissue disease, a pregnancy, a cancer or a treatment with antiplatelet agents. TTP requires a rapid diagnosis and an adapted management in emergency, which allows current remission rates of 80 to 90%. Maximal measures of resuscitation may be required. Daily sessions of therapeutical plasma exchange (TPE) until durable platelet count recovery remain the basis of management of acquired TTP. In the last few years, the anti-CD20 monoclonal antibody rituximab has been increasingly used in patients with a suboptimal response to standard treatment, such as those with refractory disease (∼10% of cases) or an exacerbation of the disease despite intensive TPE (∼50% of cases). Rituximab prevents 1-year but not long-term relapses. Further studies should specify the optimal schedule of rituximab administration and its role as a prophylactic treatment in asymptomatic patients with severe acquired ADAMTS13 deficiency that persists even in disease remission. In hereditary TTP, also known as Upshaw-Schulman syndrome (USS), a diagnosis early in life is mandatory. Prophylactic infusions of plasma should be performed in chronic relapsing forms to prevent long-term organ complications, which have to be assessed accurately and regularly. In the upcoming years, new targeted therapies evaluated through international trials should further improve the management of these diseases. Consensual guidelines for the treatment of very specific and rare situations (such as management during pregnancy in USS patients and prevention of relapses in chronic relapsing acquired TTP) should arise from the shared experience of national groups.

Thrombotic Thrombocytopenic Purpura in Patients with Systemic Lupus Erythematosus

Clinical characteristics of systemic lupus erythematosus associated thrombotic thrombocytopenic purpura

Clinical-pathological Features and Prognosis of Thrombotic Thrombocytopenic Purpura in Patients with Lupus Nephritis.

Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura:Report of Three Cases

Systemic Lupus Erythematosus (SLE) with Acute Nephritis, Antineutrophil Cytoplasmic Antibody- (ANCA-) Associated Vasculitis, and Thrombotic Thrombocytopenic Purpura (TTP): A Rare Case Report with Literature Review

A 21-Year-old Woman with Thrombotic Thrombocytopenic Purpura As Initial Symptom of Systemic Lupus Erythematosus and a Literature Review.

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Lupus Nephritis Combined with Renal Injury Due to Thrombotic Thrombocytopaenic Purpura-Haemolytic Uraemic Syndrome.

Clinical-pathological features and prognosis of thrombotic tbrombocytopenic purpura in patients with lupus nephritis

[The Dynamic Analysis and the Clinical Significance of Vascular Endothelial Cell Markers and Hemolysis Parameters in Thrombotic Thrombocytopenic Purpura].

Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases

Small Bowel Ischemia and Ischemic Colitis Secondary to Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematous: A Rare Clinical Entity

Effects of Blood Purification in the Treatment of Systemic Lupus Erythematosus Patients with Thrombotic Thrombocytopenia Purpura

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

Atypical Presentation of Thrombotic Thrombocytopenic Purpura (TTP) as an Initial Manifestation of Systemic Lupus Erythematosus (SLE) in a Young Male

Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review

Analysis of the Emergency Treatment of Patients With Thrombotic Thrombocytopenic Purpura

Clinical Analysis of 59 Patients with Thrombotic Thrombocytopenic Purpura

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China